Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Frick

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of the International AIDS Society|October 19, 2018
Using theory of change frameworks to develop evaluation strategies for research engagement: results of a pre-pilot studyKathleen M MacQueen, Natalie T Eley, Mike Frick, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 10, 2014
Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentineMike Frick, Barbara Seaworth, Lindsay McKenna, et al.
Plos One|July 25, 2022
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only differentAllison LaHood, Rifat Rahman, Lindsay McKenna, et al.
PLOS Global Public Health|August 1, 2025
Prioritizing countries for TB vaccine readiness research using a global stakeholder-centric approachMichelle M Gill, Rupali Limaye, Puck T Pelzer, et al.
The Lancet. Respiratory Medicine|April 11, 2014
The evolving role of advocacy in tuberculosisAndrea DeLuca, Erica Lessem, Donna Wegener, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Tuberculosis research and development: seeding the futureChristian Lienhardt, Alimuddin Zumla, Nebiat Gebreselassie, et al.
The Lancet. Infectious Diseases|March 24, 2025
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimensTimothy M Walker, James A Watson, David A J Moore, et al.
Frontiers in Public Health|February 2, 2026
TB vaccine development: monitoring international patent filings to anticipate access challengesMaría Florencia Pignataro, Carolinne Thays Scopel, María Lorena Bacigalupo, et al.
The Lancet. HIV|October 2, 2015
HIV viral load messages should go viral in IndiaPetros Isaakidis, Shailly Gupta, Mrinalini Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug TrialsLindsay McKenna, Mike Frick, Cynthia Lee, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of the International AIDS Society|October 19, 2018
Using theory of change frameworks to develop evaluation strategies for research engagement: results of a pre-pilot studyKathleen M MacQueen, Natalie T Eley, Mike Frick, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 10, 2014
Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentineMike Frick, Barbara Seaworth, Lindsay McKenna, et al.
Plos One|July 25, 2022
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only differentAllison LaHood, Rifat Rahman, Lindsay McKenna, et al.
PLOS Global Public Health|August 1, 2025
Prioritizing countries for TB vaccine readiness research using a global stakeholder-centric approachMichelle M Gill, Rupali Limaye, Puck T Pelzer, et al.
The Lancet. Respiratory Medicine|April 11, 2014
The evolving role of advocacy in tuberculosisAndrea DeLuca, Erica Lessem, Donna Wegener, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Tuberculosis research and development: seeding the futureChristian Lienhardt, Alimuddin Zumla, Nebiat Gebreselassie, et al.
The Lancet. Infectious Diseases|March 24, 2025
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimensTimothy M Walker, James A Watson, David A J Moore, et al.
Frontiers in Public Health|February 2, 2026
TB vaccine development: monitoring international patent filings to anticipate access challengesMaría Florencia Pignataro, Carolinne Thays Scopel, María Lorena Bacigalupo, et al.
The Lancet. HIV|October 2, 2015
HIV viral load messages should go viral in IndiaPetros Isaakidis, Shailly Gupta, Mrinalini Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug TrialsLindsay McKenna, Mike Frick, Cynthia Lee, et al.
Pageof 3